Literature DB >> 30367443

In vitro antitumor activity of progesterone in human adrenocortical carcinoma.

Martina Fragni1, Chiara Fiorentini1, Elisa Rossini1, Simona Fisogni2, Sara Vezzoli1, Sara A Bonini1, Cristina Dalmiglio3, Salvatore Grisanti3, Guido A M Tiberio4, Melanie Claps3, Deborah Cosentini3, Valentina Salvi5, Daniela Bosisio5, Massimo Terzolo6, Cristina Missale1, Fabio Facchetti2, Maurizio Memo1, Alfredo Berruti7, Sandra Sigala1.   

Abstract

PURPOSE: The management of patients with adrenocortical carcinoma (ACC) is challenging. As mitotane and chemotherapy show limited efficacy, there is an urgent need to develop therapeutic approaches. The aim of this study was to investigate the antitumor activity of progesterone and explore the molecular mechanisms underlying its cytotoxic effects in the NCI-H295R cell line and primary cell cultures derived from ACC patients.
METHODS: Cell viability, cell cycle, and apoptosis were analyzed in untreated and progesterone-treated ACC cells. The ability of progesterone to affect the Wnt/β-catenin pathway in NCI-H295R cells was investigated by immunofluorescence. Progesterone and mitotane combination experiments were also performed to evaluate their interaction on NCI-H295R cell viability.
RESULTS: We demonstrated that progesterone exerted a concentration-dependent inhibition of ACC cell viability. Apoptosis was the main mechanism, as demonstrated by a significant increase of apoptosis and cleaved-Caspase-3 levels. Reduction of β-catenin nuclear translocation may contribute to the progesterone cytotoxic effect. The progesterone antineoplastic activity was synergically increased when mitotane was added to the cell culture medium.
CONCLUSIONS: Our results show that progesterone has antineoplastic activity in ACC cells. The synergistic cytotoxic activity of progesterone with mitotane provides the rationale for testing this combination in a clinical study.

Entities:  

Keywords:  Adrenocortical carcinoma; Cell viability; Progesterone; Progesterone receptor

Mesh:

Substances:

Year:  2018        PMID: 30367443     DOI: 10.1007/s12020-018-1795-x

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  5 in total

1.  Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer.

Authors:  Elisa Rossini; Mariangela Tamburello; Andrea Abate; Silvia Beretta; Martina Fragni; Manuela Cominelli; Deborah Cosentini; Constanze Hantel; Federica Bono; Salvatore Grisanti; Pietro Luigi Poliani; Guido A M Tiberio; Maurizio Memo; Sandra Sigala; Alfredo Berruti
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-26       Impact factor: 5.555

2.  Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient With Metastatic Adrenocortical Carcinoma.

Authors:  Deborah Cosentini; Antonella Turla; Ornella Carminati; Salvatore Grisanti; Vittorio Domenico Ferrari; Marta Laganà; Giovanni Rosti; Sandra Sigala; Alfredo Berruti
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-22       Impact factor: 5.555

Review 3.  An update on adrenocortical cell lines of human origin.

Authors:  Sandra Sigala; Elisa Rossini; Andrea Abate; Mariangela Tamburello; Stefan R Bornstein; Constanze Hantel
Journal:  Endocrine       Date:  2022-06-28       Impact factor: 3.925

4.  Cytotoxic Effect of Trabectedin In Human Adrenocortical Carcinoma Cell Lines and Primary Cells.

Authors:  Andrea Abate; Elisa Rossini; Sara Anna Bonini; Martina Fragni; Deborah Cosentini; Guido Albero Massimo Tiberio; Diego Benetti; Constanze Hantel; Marta Laganà; Salvatore Grisanti; Massimo Terzolo; Maurizio Memo; Alfredo Berruti; Sandra Sigala
Journal:  Cancers (Basel)       Date:  2020-04-09       Impact factor: 6.639

Review 5.  Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma.

Authors:  Chiara Fiorentini; Salvatore Grisanti; Deborah Cosentini; Andrea Abate; Elisa Rossini; Alfredo Berruti; Sandra Sigala
Journal:  J Oncol       Date:  2019-04-01       Impact factor: 4.375

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.